Responses
Poster Presentation
A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
Compose a Response to This Article
Other responses
No responses have been published for this article.